Navigation Links
Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share

HARBIN, China, Jan. 18, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals, and other health and nutritional products in the People's Republic of China, today announced preliminary revenue and net income results for fiscal 2010.

For the fiscal year ended December 31, 2010, the Company expects to report net revenues of $77.8 million, representing a 64% increase from revenues of $47.5 million reported for fiscal 2009. The Company also expects to report net income of $31.2 million, which represents an increase of 100% from $15.6 million reported for fiscal 2009, and earnings per share of $1.04.

Commenting on the figures, Mr. Yin Wang, Chairman and CEO of Weikang, said, "2010 was an outstanding year of growth for Weikang, driven largely by the launch of multiple products under our Rongrun and TianFang brands. Our preliminary 2010 financial results far exceeded our September guidance of $55 million in revenues and $21 million in net income, and we remain very optimistic about our business prospects in 2011. We maintain our 2011 guidance of 30% to 50% revenue growth over 2010 and approximately 60% gross margin due to increased sales of high-margin products as a percent of total revenue, and we look forward to providing a complete picture of our 2010 financial results when we file with the SEC in March."

About Weikang Bio-Technology Group Co., Inc.Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd. For more information, please visit

Safe Harbor StatementCertain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Investor Relations Contact:Paul Kuntz, Senior SpecialistRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 0Email: info@redchip.comJing Zhang, Chief RepresentativeRedChip Companies Beijing OfficeTel: +86 10-8591-0635Web:

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
2. Weikang Bio-Technology Announces Filing for NASDAQ Listing
3. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
4. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
5. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
Breaking Medicine News(10 mins):